Compare · DRNA vs EIDX
DRNA vs EIDX
Side-by-side comparison of Dicerna Pharmaceuticals, Inc. (DRNA) and Eidos Therapeutics, Inc. (EIDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRNA and EIDX operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- DRNA carries a market cap of $2.96B.
- DRNA has more recent analyst coverage (14 ratings vs 0 for EIDX).
- Company
- Dicerna Pharmaceuticals, Inc.
- Eidos Therapeutics, Inc.
- Price
- $38.23+0.61%
- -
- Market cap
- $2.96B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2018
- News (4w)
- 0
- 0
- Recent ratings
- 14
- 0
Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Latest DRNA
- Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
- SEC Form 15-12B filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form 4: Koppel Adam closing all direct ownership in the company
- SEC Form 4: Zeng Ling closing all direct ownership in the company
- SEC Form 4: Weissman James B closing all direct ownership in the company
- SEC Form 4: Smith Cynthia closing all direct ownership in the company
Latest EIDX
- BIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial Officer
- BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update
- SEC Form 15-12B filed
- SEC Form 4: C Jonathan Fox gifted 500 units of Common Stock, decreasing ownership by 100% to 0 units
- SEC Form 4 filed by Douglas Rohlen
- SEC Form 4 filed by Franco Valle
- SEC Form 4: Cameron Turtle decreased ownership by 100% to 0 units
- SEC Form 4 filed by J. Ali Satvat
- SEC Form 4 filed by William Lis
- SEC Form 4 filed by Sawochka Suzanne Hooper